The RTS,S malaria vaccine candidate that is currently undergoing a phase 3 efficacy trial in areas of different transmission intensities in Africa [27,28] is derived from the 3D7 strain of P. falciparum and comprises part of the repeat, Th2R and Th3R regions of the CSP. Here, DNAJC5 is linked to malaria.